Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03671889 · ClinicalTrials.gov registry record · NA

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

A NA study of Alzheimer Disease, sponsored by InSightec.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
10
Study locations

NCT03671889 is a NA study of Alzheimer Disease that is actively recruiting participants, run by InSightec. The registered enrollment target is 50 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03671889, a NA study of Alzheimer Disease, is actively recruiting participants, sponsored by InSightec.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

Conditions Studied

Alzheimer Disease

Interventions

  • DEVICE Blood Brain Barrier (BBB) Disruption

Study Locations (10)

Florida

  • Delray Medical Center & Florida Atlantic University - Delray Beach
  • Broward Health Medical Center & The University of Florida - Fort Lauderdale
  • University of Florida Health Shands - Gainesville
  • Baptist Health South Florida & Florida International University - Miami
  • Advent Health - Orlando
  • Tampa General Hospital - Tampa

New York

  • Weill Cornell Medicine - New York

Ohio

  • The Ohio State University -Wexner Medical Center - Columbus

Texas

  • University of Texas Southwestern Medical Center - Dallas

West Virginia

  • West Virginia University Rockefeller Neuroscience Center - Morgantown

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-09-28
Est. Completion 2030-01
Phase NA

Sponsor

InSightec

38 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03671889

The ClinicalTrials.gov registry entry for NCT03671889 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The listed sponsor is InSightec, which has 38 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Blood Brain Barrier (BBB) Disruption is the first listed.

NCT03671889 reports 10 study locations spanning 5 distinct geographic areas - top geographies include Florida, New York, Ohio.

Frequently Asked Questions

What is clinical trial NCT03671889 about?

NCT03671889 is a clinical study titled "ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).

What is the current status of trial NCT03671889?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2018-09-28. Estimated completion is 2030-01.

What conditions does trial NCT03671889 study?

This clinical trial studies the following conditions: Alzheimer Disease.

What interventions are being tested in trial NCT03671889?

The interventions under investigation include: Blood Brain Barrier (BBB) Disruption (DEVICE).

Who is sponsoring clinical trial NCT03671889?

This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03671889 being conducted?

This trial has 10 study locations across Florida, New York, Ohio, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Alzheimer Disease

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.